AstraZeneca arthritis drug has mixed results in Phase III trial

LONDON, April 5 Fri Apr 5, 2013 2:14am EDT

LONDON, April 5 (Reuters) - AstraZeneca's experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.

It achieved a statistically significant improvement in a test assessing signs and symptoms of the disease, but failed to show an improvement in an X-ray endpoint, according to results from the OSKIRA-1 Phase III study.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.